Access to Medicines
More about the ongoing talks at WTO to increase access to essential medicines, especially in developing countries.
Please find all related articles below.
Brussels, 17 May – In a seminar hosted yesterday by the Group of the Progressive Alliance of Socialists & Democrats (S&D) in the European Parliament and the Member of the European Parliament (MEP) Alejandro Cercas (S&D, Spain), six MEPs from various political groups (1) along with representatives of governments, leading academics, researches and public health organisations (2) met to raise awareness about one of the most alarming issues that European healthcare systems (...)
When discussing the topic of access to medicines in the context of the economic crisis we have to consider three determinants: affordability and availability, in terms of access to medicines, and innovation in terms of developing new methods of assuring best possible health outcomes.
Usually, health expenditures are mostly covered by public funding and supplemented by private spending. The economic crisis has forced public expending to be cut making patient co-payment (...)
Clinical trials are “Investigations in humans intended to discover or verify the effects of one or more investigational medicinal products (IMPs)”. Trials conducted in the European Union (EU) are currently governed by Directive 2001/20/EC (the Clinical Trials Directive, CTD) but these guidelines have been implemented differently across member states, thereby failing to reduce red tape and increasing costs. Consequently, in July 2012, the Commission published its (...)
This high level meeting revolved around various political processes linked to the economic crisis. Some of the topics discussed include implementation of the Europe 2020 strategy, as well as pharmaceutical legislation for ensuring that people living in Europe have access to a wide range of quality and affordable medicines.
The meeting hosted by Mr Alejandro Cercas, MEP (Spain,S&D) and by the Socialists and Democrats in the European Parliament (S&D Group) served to assess the impact (...)
On 18 April, the European Parliament (EP) voted on a Resolution on the impact of the financial and economic crisis on human rights. The resolution highlighted some of the global impacts of the crisis on the right to health. EPHA applauds the EP’s recognition of the multiple impacts of the crisis on ordinary people and the need to further champion public health across Europe.
The Resolution states that "the rising price of medicines (by up to 30%) is having a negative impact on the (...)
On 9 April 2013, EPHA member Medecins du Monde European office (MdM) launched a new report that documents the effects of the economic crisis and rising xenophobia on undocumented migrants and other vulnerable groups at risk of exclusion from healthcare systems. Results show that the consequences of austerity measures are particularly strong in Southern Europe where many undocumented migrants are living in an administrative limbo. They are being joined by increasing numbers of European (...)
The third annual Flu Summit organised by EPHA member the European Scientific Working Group on Influenza will take place on 2 May 2013 in Brussels. It will be an opportunity to learn about and discuss with experts issues such as pandemic preparedness, new influenza target groups, and vaccination strategies.
This year’s edition focuses on new developments and challenges in the influenza field, with special attention for discussions on safety and effectiveness of influenza vaccines. (...)
The European Medicines Agency (EMA) organised a workshop on Medication Errors on 28 February – 1 March, a timely event given that such incidents are much more frequent across Europe than is commonly known. They are the most common preventable cause of adverse events in medication practice.
The workshop was opened by EMA Director Guido Rasi who stated that, although the reporting of suspected adverse drug reactions to the EMA-administered EudraVigilance database forms an integral part (...)
Antimicrobial Resistance (AMR)
Antimicrobial Resistance (AMR) – EP report - EU-wide plan to tackle the proliferation of AMR
Antimicrobial resistance (AMR) has been described as one of the biggest threats to public health - a worrisome development since resistance to drugs designed to treat severe diseases is becoming more widespread. In 2001 the WHO published its Global Strategy for Containment of Antimicrobial Resistance, describing what AMR is and what strategies should be (...)